Page last updated: 2024-11-04

carcinine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Carcinine is a naturally occurring beta-alanine derivative found in various organisms, including marine invertebrates, bacteria, and mammals. It exhibits a range of biological activities, including antioxidant, anti-inflammatory, and neuroprotective properties. Carcinine is synthesized through the decarboxylation of histidine followed by the condensation with beta-alanine. Its antioxidant properties are attributed to its ability to scavenge free radicals and protect cells from oxidative damage. Research suggests that carcinine may play a role in protecting against neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. Its neuroprotective effects are thought to be mediated by its ability to enhance neuronal survival and reduce oxidative stress. Carcinine is also being investigated for its potential therapeutic applications in other conditions, such as cancer, diabetes, and cardiovascular disease. The study of carcinine is motivated by its diverse biological activities and its potential to contribute to the development of novel therapeutic strategies for various diseases.'

carcinine: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

carcinine : A beta-alanine derivative that is the amide obtained by formal condensation of the carboxy group of beta-alanine with the primary amino group of histamine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2574
CHEMBL ID461024
CHEBI ID131429
CHEBI ID95262
SCHEMBL ID2819350
SCHEMBL ID19051459
MeSH IDM0064048

Synonyms (57)

Synonym
smr001233178
carcinine
MLS002153803
BPBIO1_000446
56897-53-1
NCGC00015221-02
lopac-c-2321
cas-56897-53-1
NCGC00015221-01
SMP2_000161
PRESTWICK3_000422
C16003
BSPBIO_000404
LOPAC0_000210
PRESTWICK2_000422
SPBIO_002343 ,
PRESTWICK0_000422
PRESTWICK1_000422
NCGC00015221-03
CHEMBL461024
HMS1569E06
3-amino-n-[2-(1h-imidazol-5-yl)ethyl]propanamide
beta-alanyl-histamine
CHEBI:131429
beta-alanylhistamine
beta-alaninylhistamine
n-[2-(1h-imidazol-4-yl)ethyl]-beta-alaninamide
HMS2096E06
AKOS006271690
CCG-204305
unii-wiv0w167tc
propanamide, 3-amino-n-(2-(1h-imidazol-4-yl)ethyl)-
wiv0w167tc ,
n-(2-(1h-imidazol-5-yl)ethyl)-3-aminopropanamide
HMS2235I06
AKOS013465881
propanamide, 3-amino-n-(2-(1h-imidazol-5-yl)ethyl)-
carcinine [who-dd]
.beta.-alanylhistamine
decarboxy carnosine
HMS3371N06
SCHEMBL2819350
carcinine ditrifluoroacetate
DTXSID90205421
SCHEMBL19051459
CHEBI:95262
n-beta-alanylhistamine
Q27892933
Z1198154574
hjd ,
n-[2-(1h-imidazol-5-yl)ethyl]-beta-alaninamide
3-amino-n-[2-(1h-imidazol-5-yl)ethyl]propanamide;
A869817
EN300-8092791
3-amino-n-[2-(1h-imidazol-4-yl)ethyl]propanamide
HY-107567
CS-0028884

Research Excerpts

Overview

Carinine is a natural imidazole-containing peptide derivative. Carcinine synthetase is a soluble enzyme that requires the presence of ATP, beta-alanine, and histamine.

ExcerptReferenceRelevance
"Carcinine is a natural imidazole-containing peptide derivative. "( Whole-cell biotransformation for large scale production of carcinine in Escherichia coli.
Liu, W; Liu, Z; Qi, F; Song, X; Xia, K; Zhao, M; Zhao, T; Zheng, Y, 2022
)
2.41
"Thus carcinine appears to be a product of histamine catabolism."( [Biosynthesis of carcinine (beta-alanyl-histamine) in vivo].
Arnould, JM, 1985
)
1.06
"Carcinine synthetase is a soluble enzyme that requires the presence of ATP, beta-alanine, and histamine."( [Demonstration of carcinine synthetase, a new enzyme catalysing the metabolism of histamine in the central nervous system of Carcinus maenas].
Arnould, JM, 1987
)
1.33

Bioavailability

ExcerptReferenceRelevance
" It is demonstrated in this work that both non-hydrolyzed carnosine and carcinine are characterized by greater bioavailability than pure l-carnosine subjected to enzymatic hydrolysis with carnosinase, and perform the detoxification of the α,β-unsaturated carbonyl compounds present in tobacco smoke."( The detox strategy in smoking comprising nutraceutical formulas of non-hydrolyzed carnosine or carcinine used to protect human health.
Babizhayev, MA, 2014
)
0.85

Dosage Studied

ExcerptRelevanceReference
"Prospective dose-response study."( Hemodynamic effects of carcinine in the anesthetized, instrumented, open-chest rat.
Notterman, DA; Steinberg, C, 1996
)
0.6
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
crustacean metaboliteAn animal metabolite produced by arthropods such as crabs, lobsters, crayfish, shrimps and krill.
antioxidantA substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
organooxygen compoundAn organochalcogen compound containing at least one carbon-oxygen bond.
organonitrogen compoundAny heteroorganic entity containing at least one carbon-nitrogen bond.
beta-alanine derivative
monocarboxylic acid amideA carboxamide derived from a monocarboxylic acid.
imidazolesA five-membered organic heterocycle containing two nitrogen atoms at positions 1 and 3, or any of its derivatives; compounds containing an imidazole skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (28)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency28.18380.044717.8581100.0000AID485294
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency89.12510.631035.7641100.0000AID504339
thyroid stimulating hormone receptorHomo sapiens (human)Potency25.11890.001318.074339.8107AID926; AID938
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency20.81140.00207.533739.8107AID891
cytochrome P450 2C19 precursorHomo sapiens (human)Potency16.27100.00255.840031.6228AID899
chromobox protein homolog 1Homo sapiens (human)Potency19.95260.006026.168889.1251AID540317
importin subunit beta-1 isoform 1Homo sapiens (human)Potency35.48135.804836.130665.1308AID540263
snurportin-1Homo sapiens (human)Potency35.48135.804836.130665.1308AID540263
gemininHomo sapiens (human)Potency0.07550.004611.374133.4983AID624296; AID624297
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency39.81070.031610.279239.8107AID884; AID885
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency0.05620.251215.843239.8107AID504327
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Histamine H3 receptorRattus norvegicus (Norway rat)Ki0.29400.00010.29638.5110AID365340
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (20)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1507782Inhibition of IL-15 (unknown origin)/IL-15Ralpha interaction in human PBMC cells assessed as reduction of IL-17 synthesis preincubated for 30 mins followed by IL-15 addition measured after 48 hrs by ELISA2017European journal of medicinal chemistry, Aug-18, Volume: 136Pharmacophore guided discovery of small-molecule interleukin 15 inhibitors.
AID1507781Inhibition of IL-15 (unknown origin)/IL-15Ralpha interaction in human PBMC cells assessed as reduction of TNF-alpha synthesis preincubated for 30 mins followed by IL-15 addition measured after 48 hrs by ELISA2017European journal of medicinal chemistry, Aug-18, Volume: 136Pharmacophore guided discovery of small-molecule interleukin 15 inhibitors.
AID1507780Cytotoxicity against human PBMC cells up to 200 uM after 48 hrs by CellTiter 96 AQueous one solution cell proliferation assay2017European journal of medicinal chemistry, Aug-18, Volume: 136Pharmacophore guided discovery of small-molecule interleukin 15 inhibitors.
AID365340Displacement of [3H]NAMH from rat full length histamine H3 receptor expressed in rat C6 cells2008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (54)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (9.26)18.7374
1990's10 (18.52)18.2507
2000's8 (14.81)29.6817
2010's27 (50.00)24.3611
2020's4 (7.41)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.07

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.07 (24.57)
Research Supply Index4.06 (2.92)
Research Growth Index4.84 (4.65)
Search Engine Demand Index66.20 (26.88)
Search Engine Supply Index4.00 (0.95)

This Compound (30.07)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.79%)5.53%
Reviews8 (14.29%)6.00%
Case Studies0 (0.00%)4.05%
Observational1 (1.79%)0.25%
Other46 (82.14%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]